OMT as an Adjunctive Treatment in MDD (NCT05065580) | Clinical Trial Compass
CompletedNot Applicable
OMT as an Adjunctive Treatment in MDD
United States25 participantsStarted 2021-03-12
Plain-language summary
participants will be receiving OMT 1x/week for 8 weeks. Each appointment with be a duration of 30 minutes. Patients will be required to fill out PHQ-9 and SSS-8 questionnaires before beginning the study and following the conclusion of the study.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* patients 18-65, patients with diagnosis of MDD, PHQ-9 score \> 10 at screening and baseline
Exclusion Criteria:
* history of mania, hypomania, or psychosis as defined in DSM V
* current substance abuse, including abuse within the previous 6 months
* patients with a cognitive disorder or dementia
* patients with other axis I diagnosis (anxiety disorders, dissociative disorders, etc.) that was primary in the past 6 months
* receiving other forms of manual therapy during study
* authors belief that there was significant suicidal risk
* changes in medication or psychotherapy within 6 weeks of starting study or during study period
* history of migraines
* presence of any other significant organic disease (infectious, cardiac, pulmonary, gastrointestinal, renal, etc.)
* other absolute contraindications to OMT (malignancy, infection, myelopathy, severe osteoporosis, increased ICP, intracranial bleeding, fractures, etc.)
What they're measuring
1
PHQ-9 (Patient Health Questionnaire) results post treatment